ArticleCureus2024
Refractive Results With EyeCryl Phakic Toric Intraocular Lens Implantation in a Hospital in Medina, Saudi Arabia: A Retrospective Study.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the efficacy, safety, and stability of EyeCryl Phakic intraocular lens (IOL) implantation. METHODOLOGY: This retrospective study was conducted in Maghrabi Hospital in Medina to review 31 patients who underwent posterior chamber phakic IOL (EyeCryl Phakic IOL) for surgical correction of myopia or astigmatism. The data were collected from patient medical records after obtaining their consents.
resultsOur findings demonstrated the efficacy of a toric implantable collamer lens (ICL) for the treatment of myopic astigmatism, with a significant change in all eye measures (sphericity, axis, and cylinder) after IOL implantation for study participants in both right and left eyes. There were no intraoperative complications observed among the studied patients; however, one case required ICL repositioning due to spontaneous axis rotation. The majority of cases showed no postoperative complications except one case complaint of steroid-induced glaucoma. In this study, we observed no significant changes regarding endothelial cell loss.
conclusionIn summary, EyeCryl Phakic IOL implantation may be safe and effective for myopic astigmatism patients. It improved the visual performance of most of the studied participants without detecting serious complications. Studies with longer follow-ups are needed to observe other complications and ensure the safety of the procedure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.